113
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Use of the Uricase-Inhibited Rat as an Animal Model in Toxicology

&
Pages 47-74 | Published online: 25 Sep 2008

References

  • Lindsey J., Capen C. C. Animal models for biomedical research VI—metabolic disease (symposium). Federation Proc. 1976; 35: 1192
  • Animal Models for Biomedical Research, Symposia I, II, III and IV. Printing and Publishing Office, National Academy of Sciences, Washington, D.C. 20418
  • Kumar R. Animal models for screening new agents: a behavioural view. Brit. J. Clin. Pharmacol. 1976; 13, (Suppl.)
  • Johnson W. J., Stavric B., Chartrand A. Uricase inhibition in the rat by s‐triazines: an animal model for hyperuricemia and hyperuricosuria. Proc. Soc. Exptl. Biol. Med. 1969; 131: 8
  • Stavric B., Johnson W. J., Grice H. C. Uric acid nephropathy: an experimental model. Proc. Soc. Exptl. Biol. Med. 1969; 130: 512
  • Smith L. H., Jr. Disorders of Purine Metabolism. Cecil‐Loeb, Textbook of Medicine13th ed., P. B. Beeson, W. McDermott. Saunders, Philadelphia 1971; 1682
  • McLaughlin G. E., McCarty D. J., Jr., Prescott D. J. Gout and Hyperuricemia. Topics in Medicinal Chemistry, J. L. Rabinonitz, R. M. Myerson. Wiley (Interscience), New York 1970; Vol. 3: 263
  • Seegmiller J. E., Laster L., Howell R. R. Biochemistry of uric acid and its relation to gout. New Engl. J. Med. 1963; 268: 712, 764, 821
  • Gutman A. B. Renal excretion of uric acid in normal and gouty man. Arthrit. Rheum. 1965; 8: 665
  • Smyth C. J. Disorders associated with hyperuricemia. Arthrit. Rheumat. 1975; 18(Suppl. No. 6)713
  • Frank O. Observations Concerning the Incidence of Disturbance of Lipid and Carbohydrate Metabolism in Gout. Purine Metabolism in Man, O. Sperling, A. DeVries, J. B. Wyngaarden. Plenum, New York 1974; 495
  • Pearce J., Aziz H. Uric acid and plasma lipids in cerebrovascular disease. Brit. Med. J., Part I 1969; 4: 78, prevalence of hyperuricemia
  • Gibson T., Grahame R. Gout and Hyperlipidaemia. Purine Metabolism in Man, O. Sperling, A. DeVries, J. B. Wyngaarden. Plenum, New York 1974; 499
  • Lesch M., Nyhan W. L. A familial disorder of uric acid metabolism and central nervous system function. Am. J. Med. 1964; 36: 561
  • Mustard J. F., Murphy E. A., Ogryzlo M. A., Smythe H. A. Blood coagulation and platelet economy in subjects with primary gout. Canad. Med. Assoc. J. 1963; 89: 1207
  • Wallace S. L. Gout and hypertension. Arthritis Rheum. 1975; 18(Suppl. No. 6)721
  • Rakic M. T., Valkenburg H. A., Davidson R. T., Engels J. P., Mikkelsen W. M., Neel J. V., Duff I. F., Himes S. Observations on the natural history of hyperuricemia and gout. I. An eighteen year follow‐up of nineteen gouty families. Am. J. Med. 1964; 37: 862
  • Montoye H. J., Faulkner J. A., Dodge H. J., Mikkelsen W. M., Willis P. W., III, Block W. D. Serum uric acid concentration among business executives. Ann. Intern. Med. 1967; 66: 838
  • Van Peenen H. J. The causes of non‐azotemic hyperuricemia. Am. J. Clin. Pathol. 1971; 55: 698
  • McEwin R., McEwin K., Loudon B. Raised serum uric acid levels with myocardial infarction. Med. J. Australia 1974; 1: 530
  • Jacobs D. Hyperuricemia and myocardial infarction. S. Afr. Med. J. 1972; 46: 367
  • Kohn P. M., Prozan G. B. Hyperuricemia–relationship to hypercholesteremia and acute myocardial infarction. JAMA 1959; 170: 1909
  • Pochedly C. Hyperuricemia in leukemia and lymphoma. N.Y. State J. Med. 1973; 73: 1085
  • Ultmann J. E. Hyperuricemia in disseminated neoplastic disease other than lymphomas and leukemias. Cancer 1962; 15: 122
  • Phoon W. H., Pincherle G. Blood uric acid in executives. Brit. J. Ind. Med. 1972; 29: 334
  • Pfeiffer C. C., Iliev V., Nichols R. E., Sugerman A. A. The serum urate level reflects degree of stress. J. Clin. Pharmacol. 1969; 9: 384
  • Katz J. L., Weiner H., Gutman A., Yü T. ‐F. Hyperuricemia gout and the executive suite. JAMA 1973; 224: 1251
  • Schrier R. W., Hano J., Keller H. I., Finkel R. M., Gilliland P. F., Cirksena W. J., Teschon P. E. Renal, metabolic and circulatory responses to heat and exercise. Ann. Intern. Med. 1970; 73: 213
  • Emmerson B. T., Douglas W., Doherty R. L., Feigl P. Serum urate concentrations in the Australian aboriginal. Ann. Rheum. Dis. 1969; 28: 150
  • Healey L. A. Epidemiology of hyperuricemia. Arthritis Rheum. 1975; 18(Suppl. No. 6)709
  • Kasl S. V., Brooks G. W., Rodgers W. L. Serum uric acid and cholesterol in achievement behaviour and motivation I. JAMA 1970; 213: 1158
  • Editorial, Uric acid and the psyche. JAMA 1969; 208: 1180
  • Lanese R. R., Gresham G. E., Keller M. D. Behavioral and physiological characteristics in hyperuricemia. JAMA 1969; 207: 1878
  • Kennett K. F., Cropley A. J. Uric acid and divergent thinking: a possible relationship. Brit. J. Psychol. 1975; 66: 175
  • Cristofori F. C., Duncan G. G. Uric acid excretion in obese subjects during periods of total fasting. Metabolism 1964; 13: 303
  • Klinenberg J. R., Gonick H. C., Dornfeld L. Renal function abnormalities in patients with asymptomatic hyperuricemia. Arthritis Rheum. 1975; 18(Suppl. No. 6)725
  • Scott J. T. Causes of hyperuricemia. Proc. Roy. Soc. Med. 1969; 62: 19
  • Zöllner N., Griebsch A. Diet and Gout. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 435
  • Griebsch A., Zöllner N. Effect of Ribomononucleotides Given Orally on Uric Acid Production in Man. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 443
  • Zöllner N., Diet, Gout (1975) Proc. 9th Int. Congr. Nutrition. Mexico, 1972. 1: 267
  • Clifford A. J., Riumallo J. A., Young V. R., Scrimshaw N. S. Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. J. Nutr. 1976; 106: 428
  • Bell J. D., Margen S., Galloway D. H. Ketosis, weight loss, uric acid and nitrogen balance in obese women fed single nutrients at low caloric levels. Metabolism 1969; 18: 193
  • Drenick E. J., Swenseid M. E., Blahd W. H., Tuttle S. G. Prolonged starvation as treatment for severe obesity. JAMA 1974; 187: 100
  • Lloyd‐Mostyn R. H., Lord P. S., Glover R., West C., Gilliland I. C. Uric acid metabolism in starvation. Ann. Rheum. Dis. 1970; 29: 553
  • Fox I. H., Kelly W. N. Studies on the mechanism of fructoseinduced hyperuricemia in man. Metabolism 1972; 21: 713
  • Schwarzmeier J. D., Marktl W., Moser K., Lujf A. Fructoseinduced hyperuricemia. Res. Exptl. Med. 1974; 162: 341
  • Kelly W. N. Effects of drugs on uric acid in man. Ann. Rev. Pharmacol. 1975; 15: 327
  • Krakoff C. H. Clinical pharmacology of drugs which influence uric acid production and excretion. Clin. Pharmacol. The rap. 1967; 8: 124
  • Weiner I. M. Comparative pharmacology of uricosuric drugs. Gen. Pharmacol. 1976; 7: 1
  • Fanelli G. M., Jr. Uricosuric agents. Arthritis Rheum. 1975; 18(Suppl. No. 6)853
  • Emmerson B. T. Hyperuricaemia—to treat or not?. Drugs 1975; 9: 141
  • Wacker W. E. C. Man: sapient but gouty. New Engl. J. Med. 1970; 283: 151
  • Fanelli G. M., Jr., Beyer K. H., Jr. Uric acid in non‐human primates with special reference to its renal transport. Ann. Rev. Pharmacol. 1974; 14: 355
  • Duncan H., Wakim K. G., Ward L. E. The effects of intravenous administration of uric acid on its concentration in plasma and urine of Dalmatian and non‐Dalmatian dogs. J. Lab. Clin. Med. 1961; 58: 876
  • Kuster G., Shorter R. G., Dawson B., Hallenbeck G. A. Uric acid metabolism in Dalmatians and other dogs. Arch. Int. Med. 1972; 129: 492
  • Mudge G. H., Cucchi J., Platts M., O'Connell J. M. B., Berndt W. O. Renal excretion of uric acid in the dog. Am. J. Physiol. 1968; 215: 404
  • Berger L., Yü T ‐F. Urinary excretion of uric acid after instantaneous intra‐renal‐arterial injection in mongrel and Dalmatian dogs. J. Mount Sinai Hosp. 1970; 37: 351
  • Austic R. E., Cole R. K. Impaired renal decrease of uric acid in chickens having hyperuricemia and articular gout. Am. J. Physiol. 1972; 223: 525
  • Fitzgerald T. J. Anti‐inflamatory Agents, Chemistry and Pharmacology, R. A. Schener, M. W. Whitehouse. Academic, New York 1974; Vol. 1: 302
  • Grims W. A. A phase contrast study of the mechanisms of renal calcification. J. Urol. 1957; 78: 553
  • Duncan H., Wakim K. G., Ward L. E. Renal lesions resulting from induced hyperuricemia in animals. Mayo Clinic Proc. 1963; 38: 411
  • Smith J. F., Lee Y. C. Experimental uric acid nephritis in the rabbit. J. Exptl. Med. 1957; 105: 615
  • Dunn J. S., Poison C. J. Experimental uric acid nephritis. J. Pathol. Bacteriol. 1926; 29: 337
  • Fridovich I. The competitive inhibition of uricase by oxonate and by related derivatives of s‐triazines. J. Biol. Chem. 1965; 240: 2491
  • Hatfield P. J., Simmonds H. A., Cameron J. S., Jones A. S., Cadenhead A. Effects of Allopurinol and Oxonic Acid on Pyrimidine Metabolism in the Pigs. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 637
  • Gralla E. J., Crelin E. S., Osbaldiston G. W. The embryotoxic effects of a uricase inhibitor and i.v. sodium urate in rats and mice. Teratology 1975; 11: 19A
  • Redman C. W. G., Beilin L. J., Bonnar J., Wilkinson R. H. Plasma‐urate measurements in predicting fetal death in hypertensive pregnancy. Lancet 1976; 1: 1370
  • Wildman R. A., Philp R. B. Effect of allopurinol on platelets and uric acid in oxonate‐induced hyperuricemic rabbits. Proc. Canad. Federation Biol. Sci. 1970; 13: 9
  • Yü T. F., Gutman A., Berger L., Kaung C. Low uricase activity in the Dalmatian dog simulated in mongrels given oxonic acid. Am. J. Physiol. 1971; 220: 973
  • Stavric B., Nera E. A., Johnson W. J., Salem F. A. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Invest. Urol. 1973; 11: 3
  • Waisman J., Bluestone R., Klineberg J. R. A preliminary report of nephropathy in hyperuricemic rats. Lab. Invest. 1974; 30: 716
  • Lindy S., Pakarinen A. Oxonate‐induced hyperuricemia and renal accumulation of uric acid in the rat. Scand. J. Clin. Lab. Invest. 1970; 25(Supp. 113)76
  • Mwasi L. M., Waisman J., Bluestone R., Klinenberg J. R. A brief note on the ultrastructure of renal glomeruli in acutely hyperuricemic rats. Invest. Urology 1976; 13: 321
  • Stavric B., Johnson W. J., Clayman S., Gadd R. E. A., Chartrand A. Effect of fructose administration on serum levels in the uricase inhibited rat. Experientia 1976; 32: 373
  • Boda D., Penzes P., Gecse A., Streitmann K., Zsilinszky E., Karady I. Renal tubular necrosis after gastroenteritis in infants. Brit. Med. J. 1971; 1: 609
  • Boda D., Penzes P., Gesce A., Streitman K., Zsilinszky E., Karady I. Can. J. Physiol. Pharmacol. 1973; 151: 496
  • Bonardi G., Vidi A. Action of 4‐prenyl‐1,2‐diphenyl‐3, 5‐pyrazolidinedione (DA 2370) on an experimental hyperuricosuria in the rat. Pharm. Res. Commun. 1973; 5: 125
  • Norrlind B., Kihlberg R. A short assay for the estimation of dietary purine compounds using a rat model system with inhibition of uricase. J. Nutr. 1973; 103: 1262
  • Lussier A., De Medicis R. Inhibition of adjuvant‐induced arthritis in hyperuricemic rats. Scand. J. Rheumat. June 1–7, 1975, Suppl. 8, VIII Europ. Rheumat. Congress, Helsinki, Abst. 129
  • Waisman J., Mwasi L. M., Klinenberg J. R. Acute hyperuricemic nephropathy in rats. An electron microscopic study. Am. J. Pathol. 1975; 81: 367
  • Norrlind B., Kihlberg R. (1975) Plasma uric acid levels in rats given uricase inhibitor. Proc. 9th Int. Congr. Nutrition. 1972. Mexico, 3: 97
  • Bluestone R., Waisman J., Klinenberg J. R. Chronic experimental hyperuricemic nephropathy; Biochemical and morphologic characterization. Lab. Invest. 1975; 33: 273
  • Bergmann F., Kwietny‐Govrin H., Ungar‐Waron H., Kalmus A., Tamari M. Relation of structure to the inhibitory activity of purines against urate oxidase. Biochem. J. 1963; 86: 567
  • Iwata H., Yamamoto I., Gohda E., Morita K., Nishino K. Effects of 5‐diazoimidazole‐4‐carboxamide and 3‐diazopyrasole‐4‐carboxamide and related thioazo compounds on xanthine oxidase, uricase and hypoxanthine‐guanine phosphoribosyltransferase. Biochem. Pharmacol. 1972; 21: 2141
  • Iwata H., Yamamoto I., Gohda E., Morita K., Nakamura M., Sumi K. Potent competitive uricase inhibitors—2,8‐diazohypoxanthine and related compounds. Biochem. Pharmacol. 1973; 22: 2237
  • Moore F. J., Thomas R. M. Allantoxanic acid as an oxidation product of uric acid. J. Am. Chem. Soc. 1918; 40: 1120
  • Venable C. S. The action of hydrogen peroxide upon uric acid. J. Am. Chem. Soc. 1918; 40: 1099
  • Handschumacher R. E. 5‐azaorotic acid and related inhibitors of the synthesis de novo of pyrimidine nucleotides. Cancer Res. 1963; 23: 634
  • Granat P., Creasey W. A., Calabresi P., Handschumacher R. E. Investigation with 5‐azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin. Pharm. Therap. 1965; 6: 436
  • Čihak A., Šorm F. Metabolic transformations of 5‐azauracil and 5‐azaorotic acid in mouse liver and Escherichia coli. Effect on the synthesis of pyrimidines. Biochem. Pharmacol. 1972; 21: 607
  • Biltz H., Robl R. Elucidation of oxonic acid. Ber. 1920; 53B: 1967, ref. Chem. Abstr. 15, 1028 (1921) Elucidation of some transformations of oxonic acid and of allantoxaidine, Ber. 54B, 2441 (1921) ref. Chem. Abstr. 16, 1213 (1922)
  • Canellakis E. S., Cohen P. P. On the nature of oxonic acid and allantoxaidin as oxidation products of uric acid and allantoin. J. Biol. Chem. 1955; 213: 379
  • Brandenberger H. The oxidation of uric acid to oxonic acid (allantoxanic acid) and its application in tracer studies of uric acid biosynthesis. Biochem. Biophys. Acta 1954; 15: 108
  • Hartman S. C., Fellig J. On the mechanism of the oxidation of uric acid by alkaline peroxidase. J. Am. Chem. Soc. 1955; 77: 1051
  • Aldrich Handbook of Organic Chemicals. Aldrich Chemical, Milwaukee 1972; 483
  • Neville G. A., Stavric B., Swift P., to be published
  • Barlow K. A., Beilin L. J. Renal disease in primary gout. Quart. J. Med. 1968; 37: 79
  • Bluestone R., Brady S., Waisman J., Klinenberg J. Experimental hyperuricemic nephropathy. Arthritis Rheumat. 1975; 18(Suppl. No. 6)823
  • Stavric B., Nera E. A. 1972, unpublished observations
  • Stavric B., Nera E. A., Clayman S., Gadd R. E. A., Hebert D. Effect of acute hyperuricemia on selected blood parameters and reversible nephrotoxicity due to elevated uric acid in the rat. Soc. Exptl. Biol. Med., 3rd Sci. Meeting, Champlain Section, Nov. 17, 1973, Burlington, Vermont. Part of this report was already published (see Ref. ‘110’). The manuscript on reversible nephrotoxicity is in preparation
  • Nera E. A., Stavric B. Necrotic effect of urate on glomeruli in the rat kidney induced by potassium oxonate (Preliminary observations). Soc. Exptl. Biol. Med., 7th Sci. Meeting, Champlain Section, Nov. 15, 1975, Burlington, Vermont (to be published)
  • Editorial, Hyperuricemic acute renal failure. Lancet 1974; 1: 1266
  • Warren D. J., Leitch A. G., Leggett R. J. E. Hyperuricemic acute renal failure after epileptic seizures. Lancet 1975; 2: 385
  • Klinenberg J. R., Kippen I., Bluestone R. Hyperuricemic nephropathy: Pathologic features and factors influencing urate deposition. Nephron 1975; 14: 88
  • Stavric B., Johnson W. J. the Proceedings of the Canad. Federation Biol. Soc. Vol. 12, 12th Ann. Meeting, Edmonton, Alberta, June, 11‐13th1969, unpublished observations as reported in
  • Scott J. T., O'Brien P. K. Probenecid, nephrotic syndrome and renal failure. Ann. Rheum. Dis. 1968; 27: 249
  • Bianchi C., Bonardi G. Pharmacological investigations of 4‐prenyl‐1,2‐diphenyl‐3, 5‐pyrazolidinedione (DA 2370). Arzneimittel‐Forsch. 1972; 22: 196
  • Weinshilboum R. M., Goldstein J. L., Kelly W. N. Prolonged hyperuricemia associated with acute chlorprothixene ingestion. Arthritis Rheum. 1975; 18(Suppl. No. 6)739
  • Healey L. A., Harrison M., Decker J. L. Uricosuric effect of chlorprothixene. New Engl. J. Med. 1964; 272: 526
  • Karn W. N., Mead B. T., Fishman J. J. Double‐blind study of chlorprothixene (Taractan) a panpsychotropic agent. J. New Drugs 1961; 1: 72
  • Council on Drugs, Evaluation of chlorprothixene (Taractan). JAMA 1963; 186: 144
  • Stavric B., Clayman S., Gadd R. E. A., Hebert D. Some in vivo effects in the rat induced by chloroprothixene and potassium oxonate. Pharm. Res. Commun. 1975; 7: 117
  • Gutman A. B. Uricasuric drugs with special reference to probenecid and sulfinpyrazone. Advan. Pharmacol. 1966; 4: 91
  • Shapiro D. M., Shils M. E., Fugmann R. A., Friedland L. M. Quantitative biochemical differences between tumor and host as a basis for cancer chemotherapy. IV. Niacin and 2‐ethylamino‐1,3, 4‐tiadiazole. Cancer Res. 1957; 17: 29
  • Krakoff I. H., Magill G. B. Effects of 2‐ethylamino‐1,3, 4‐HC1 on uric acid production in man. Proc. Soc. Exptl. Biol. Med. 1956; 91: 470
  • Stavric B., Johnson W. J., Chartrand A. Effect of some diuretics on hyperuricemic rats. 1972, unpublished observations
  • Postlethwaite A. E., Kelley W. N. Uricosuric effect of radiocontrast agents. Ann. Intern. Med. 1971; 74: 845
  • Emmerson B. T. Effect of oral fructose on urate production. Ann. Rheum. Dis. 1974; 33: 276
  • Stirpe F., Della Corte E., Bonetti E., Abbondanza A., Abbati A., de Stefano F. Fructose‐induced hyperuricemia. Lancet 1970; 2: 1310
  • Heuckenkamp P. U., Zöllner N. Fructose‐induced hyperuricemia. Lancet 1971; 1: 808
  • Simkin P. A. Hexose infusions in Cebus monkeys: effects on uric acid metabolism. Metabolism 1972; 21: 1029
  • Robinson J. W., Food Technicol Service Staff. Food Engineering. May, 1975; 57
  • Food Engineering. May, 1975; 55, Research Report, Food sweeteners enter a new era
  • MacLaughlan M. J., Rodnan G. P. Effects of food, fast and alcohol on serum uric acid and acute attacks of gout. Am. J. Med. 1967; 42: 38
  • Newcombe D. S. Ethanol metabolism and uric acid. Metabolism 1972; 21: 1193
  • Healey L. A. Port wine and the gout. Arthritis Rheum. 1975; 18(Suppl. No. 6)659
  • Yü T. F., Sirota J. H., Berger L., Halpern M., Gutman A. B. Effect of sodium lactate infusion on urate clearance in man. Proc. Soc. Exptl. Biol. Med. 1957; 96: 809
  • Gömöri P., Zolnai B., Nagy Z., Jakab I. The problem of renal ischemia and of the arterio‐venosus anastomoses of the kidney. Acta Med. Acad. Sci., Hung. 1964; 20: 169
  • Balint P., Fekete A., Szalay E., Taraba I. The effect of anaesthesia on the course of acute renal failure. Naunym‐Schmiedelberg. Arch. Exptl. Pathol. Pharmakol. 1960; 239: 497
  • Herz R., Sauter V., Bircher J. Fortuitous discovery of urate nephrolithiasis in rats subjected to portacaval anastomosis. Experientia 1972; 28: 27
  • Henderson J. F. Purine metabolism and human disease. Clin. Biochem. 1969; 2: 241
  • Boyd E. M., Dolman M., Knight L. M. The chronic oral toxicity of caffeine. Can. J. Physiol. Pharmacol. 1965; 43: 995
  • Solyom L., Enesco H. E., Beaulieu C. The effects of RNA, uric acid and caffeine on conditioning and activity in rats. J. Psychiat. Res. 1968; 6: 175
  • Newland H. Antagonism of the anti‐thrombotic effect of Warfarin by uric acid. Am. J. Med. Sci. 1968; 256: 44
  • Dreyfuss F., Zahavi J. Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease. Atherosclerosis 1973; 17: 107
  • Elion G. B., Bieber S., Nathan H., Hitchings G. H. Uracil antagonism and inhibition of mammary adenocarcinoma 755. Cancer Res. 1958; 18: 802
  • Čihak A., Šorm F. Metabolic transformations of 5‐azaorotate: Cause of marked inhibition of orotidine‐5′‐phosphate decarboxylase. Biochim. Biophys. Acta 1967; 149: 314
  • Rubin R. J., Reynard A., Handschumacher R. E. An analysis of the lack of drug synergism during sequential blockade of de novo pyrimidine biosynthesis. Cancer Res. 1964; 24: 1002
  • Stevens H. A. A multi‐disciplinary catalogue of uric acid. Perceptual and Motor Skills 1973; 36: 1007

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.